Purple Biotech (PPBT) director details shares, RSUs and stock options

Rhea-AI Filing Summary

PURPLE BIOTECH LTD. director Robert E. Gagnon filed a Form 3 disclosing his equity stake in the company. He reports 3,062,500 Ordinary Shares held directly, including 2,454,167 unvested restricted stock units that vest over time and settle in Ordinary Shares.

Gagnon also holds three stock option awards: options for 112,500 Ordinary Shares at an exercise price of $0.146765625 per share expiring on December 29, 2026; options for 300,000 Ordinary Shares at $0.059375 per share expiring on April 24, 2028; and options for 2,650,000 Ordinary Shares at $0.00309375 per share expiring on October 21, 2030. The filing states that the Ordinary Shares may be represented by American Depositary Shares, with each ADS currently equal to 2,000 Ordinary Shares. No purchases or sales are reported; this is an initial ownership disclosure.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gagnon Robert E.

(Last) (First) (Middle)

14 WHITRIDGE RD

(Street)

NATICK MASSACHUSETTS 01760

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
PURPLE BIOTECH LTD. [ PPBT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	3,062,500(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	(2)	Ordinary Shares	112,500	(2)	D
Stock Option (Right to Buy)	(3)	(3)	Ordinary Shares	300,000	(3)	D
Stock Option (Right to Buy)	(4)	(4)	Ordinary Shares	2,650,000	(4)	D

Explanation of Responses:

1. Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares

2. Represents stock option to purchase 112,500 Ordinary Shares (equivalent to 56 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.146765625 per Ordinary Share and the option expires on December 29, 2026.

3. Represents stock option to purchase 300,000 Ordinary Shares (equivalent to 150 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 274,997 Ordinary Shares are vested and exercisable, with the remaining options to purchase 25,003 Ordinary Shares vesting in equal quarterly installments until April 24,2026.The exercise price of this stock option is $0.059375 per Ordinary Share and the option expires on April 24, 2028.

4. Represents stock option to purchase 2,650,000 Ordinary Shares (equivalent to 1,325 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 220,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 2,429,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2029.The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030.

	/s/ Robert Gagnon	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Robert E. Gagnon report in his Purple Biotech (PPBT) Form 3?

He reports his initial beneficial ownership in Purple Biotech, including 3,062,500 Ordinary Shares and multiple stock option grants. This filing establishes his starting equity position as a director, without showing any recent purchases or sales of shares.

How many unvested RSUs does Robert E. Gagnon hold in Purple Biotech (PPBT)?

He holds 2,454,167 unvested restricted stock units, each representing one Ordinary Share. These RSUs vest over time based on service conditions and are settled in Ordinary Shares, providing additional potential equity as they vest and convert into stock.

What stock option grants are disclosed for Robert E. Gagnon at Purple Biotech (PPBT)?

He has options for 112,500 Ordinary Shares at $0.146765625, 300,000 shares at $0.059375, and 2,650,000 shares at $0.00309375. These options were issued under the 2016 Equity-Based Incentive Plan with expirations in 2026, 2028, and 2030.

Are any of Robert E. Gagnon’s Purple Biotech (PPBT) stock options already vested?

Yes. All 112,500-share options are fully vested and exercisable. Of the 300,000-share grant, 274,997 are vested; for the 2,650,000-share grant, 220,833 are vested. Remaining portions vest in equal quarterly installments through 2026 and 2029, respectively.

How are Purple Biotech (PPBT) Ordinary Shares represented by American Depositary Shares (ADSs)?

Each American Depositary Share currently represents 2,000 Ordinary Shares of Purple Biotech. The filing notes this ratio when describing the scale of Gagnon’s option grants, translating underlying Ordinary Shares into an equivalent ADS count for reference.

Does Robert E. Gagnon’s Purple Biotech (PPBT) Form 3 show any insider buying or selling?

No. The Form 3 lists holdings and derivative positions but shows no purchases or sales. Transaction summary data indicate zero buy or sell transactions, meaning this filing is a baseline ownership disclosure, not a record of trading activity.